225 related articles for article (PubMed ID: 28823642)
1. Elevated IL-31 serum levels in bullous pemphigoid patients correlate with eosinophil numbers and are associated with BP180-IgE.
Salz M; Haeberle S; Hoffmann J; Enk AH; Hadaschik EN
J Dermatol Sci; 2017 Sep; 87(3):309-311. PubMed ID: 28823642
[No Abstract] [Full Text] [Related]
2. Serum levels of IgE anti-BP180 and anti-BP230 autoantibodies in patients with bullous pemphigoid.
Ishiura N; Fujimoto M; Watanabe R; Nakashima H; Kuwano Y; Yazawa N; Echigo T; Okochi H; Tamaki K
J Dermatol Sci; 2008 Feb; 49(2):153-61. PubMed ID: 17920818
[TBL] [Abstract][Full Text] [Related]
3. Circulating IgE anti-BP180 autoantibody and its correlation to clinical and laboratorial aspects in bullous pemphigoid patients.
Ma L; Wang M; Wang X; Chen X; Zhu X
J Dermatol Sci; 2015 Apr; 78(1):76-7. PubMed ID: 25797173
[No Abstract] [Full Text] [Related]
4. Possible correlation of IgE autoantibody to BP180 with disease activity in bullous pemphigoid.
Kamiya K; Aoyama Y; Noda K; Miyake T; Yamaguchi M; Hamada T; Tokura Y; Iwatsuki K
J Dermatol Sci; 2015 Apr; 78(1):77-9. PubMed ID: 25771164
[No Abstract] [Full Text] [Related]
5. Elevated levels of circulating immunoglobulin E autoantibodies against BP180 and BP230 in an intractable case of bullous pemphigoid.
Akasaka E; Hagiwara C; Takiyoshi N; Aizu T; Nakano H; Sawamura D; Ota T
J Dermatol Sci; 2016 Oct; 84(1):110-113. PubMed ID: 27492811
[No Abstract] [Full Text] [Related]
6. Levels of anti-BP180 NC16A IgE do not correlate with severity of disease in the early stages of bullous pemphigoid.
Bing L; Xiping Z; Li L; Jun P; Yi-Xia W; Min Y; Qing L; Qiu-Ning S; Hong-Zhong J; Ya-Gang Z
Arch Dermatol Res; 2015 Nov; 307(9):849-54. PubMed ID: 26404084
[TBL] [Abstract][Full Text] [Related]
7. High serum anti-BP180 IgE levels correlate to prominent urticarial lesions in patients with bullous pemphigoid.
Cho YT; Liao SL; Wang LF; Chu CY
J Dermatol Sci; 2016 Jul; 83(1):78-80. PubMed ID: 27021592
[No Abstract] [Full Text] [Related]
8. Bullous pemphigoid with hyperkeratosis and palmoplantar keratoderma: Three cases.
Fania L; Didona D; Pacifico V; Mariotti F; De Luca N; Abeni D; Mazzanti C; Di Zenzo G; Didona B
J Dermatol; 2018 Sep; 45(9):1135-1140. PubMed ID: 30007013
[TBL] [Abstract][Full Text] [Related]
9. Decrease in eosinophils infiltrating into the skin of patients with dipeptidyl peptidase-4 inhibitor-related bullous pemphigoid.
Chijiwa C; Takeoka S; Kamata M; Tateishi M; Fukaya S; Hayashi K; Fukuyasu A; Tanaka T; Ishikawa T; Ohnishi T; Watanabe S; Tada Y
J Dermatol; 2018 May; 45(5):596-599. PubMed ID: 29411416
[TBL] [Abstract][Full Text] [Related]
10. Correlation of Serum Levels of IgE Autoantibodies Against BP180 With Bullous Pemphigoid Disease Activity.
van Beek N; Lüttmann N; Huebner F; Recke A; Karl I; Schulze FS; Zillikens D; Schmidt E
JAMA Dermatol; 2017 Jan; 153(1):30-38. PubMed ID: 27829102
[TBL] [Abstract][Full Text] [Related]
11. A new clinical variant of acquired reactive perforating dermatosis-like bullous pemphigoid.
Schauer F; Kern JS; Virtic O; Technau-Hafsi K; Meiss F; Thoma K; Athanasiou I; Sitaru C; Di Zenzo G; Izumi K; Nishie W; Shimizu H; Bruckner-Tuderman L; Kiritsi D
Br J Dermatol; 2019 Jan; 180(1):231-232. PubMed ID: 30188568
[No Abstract] [Full Text] [Related]
12. Bullous pemphigoid with linear lesions and antibodies exclusively against the soluble ectodomain of BP180 (LAD-1).
Mahmoudi H; Toosi R; Kamyab K; Zillikens D; Schmidt E; Daneshpazhooh M
J Dtsch Dermatol Ges; 2019 Sep; 17(9):933-935. PubMed ID: 31353797
[No Abstract] [Full Text] [Related]
13. Immunoglobulin E and bullous pemphigoid.
Cozzani E; Gasparini G; Di Zenzo G; Parodi A
Eur J Dermatol; 2018 Aug; 28(4):440-448. PubMed ID: 30325326
[TBL] [Abstract][Full Text] [Related]
14. Biological and Clinical Response to Omalizumab in a Patient with Bullous Pemphigoid.
Menzinger S; Kaya G; Schmidt E; Fontao L; Laffitte E
Acta Derm Venereol; 2018 Feb; 98(2):284-286. PubMed ID: 29136264
[No Abstract] [Full Text] [Related]
15. IgE recognition of bullous pemphigoid (BP)180 and BP230 in BP patients and elderly individuals with pruritic dermatoses.
Fania L; Caldarola G; Müller R; Brandt O; Pellicano R; Feliciani C; Hertl M
Clin Immunol; 2012 Jun; 143(3):236-45. PubMed ID: 22534318
[TBL] [Abstract][Full Text] [Related]
16. Unraveling the significance of IgE autoantibodies in organ-specific autoimmunity: lessons learned from bullous pemphigoid.
Messingham KA; Holahan HM; Fairley JA
Immunol Res; 2014 Aug; 59(1-3):273-8. PubMed ID: 24845463
[TBL] [Abstract][Full Text] [Related]
17. IgG4 and IgE are the major immunoglobulins targeting the NC16A domain of BP180 in Bullous pemphigoid: serum levels of these immunoglobulins reflect disease activity.
Döpp R; Schmidt E; Chimanovitch I; Leverkus M; Bröcker EB; Zillikens D
J Am Acad Dermatol; 2000 Apr; 42(4):577-83. PubMed ID: 10727301
[TBL] [Abstract][Full Text] [Related]
18. IgE-mediated mechanisms in bullous pemphigoid and other autoimmune bullous diseases.
van Beek N; Schulze FS; Zillikens D; Schmidt E
Expert Rev Clin Immunol; 2016; 12(3):267-77. PubMed ID: 26588556
[TBL] [Abstract][Full Text] [Related]
19. Enzyme-linked Immunoassay Index for Anti-NC16a IgG and IgE Auto-antibodies Correlates with Severity and Activity of Bullous Pemphigoid.
Kalowska M; Ciepiela O; Kowalewski C; Demkow U; Schwartz RA; Wozniak K
Acta Derm Venereol; 2016 Feb; 96(2):191-6. PubMed ID: 25791894
[TBL] [Abstract][Full Text] [Related]
20. Pathogenicity of IgE in autoimmunity: successful treatment of bullous pemphigoid with omalizumab.
Fairley JA; Baum CL; Brandt DS; Messingham KA
J Allergy Clin Immunol; 2009 Mar; 123(3):704-5. PubMed ID: 19152970
[No Abstract] [Full Text] [Related]
[Next] [New Search]
